CAS NO: | 80321-69-3 |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
生物活性 | Gypenoside XVII, a novel phytoestrogen belonging to the gypenosides, can activateestrogen receptors. | ||||||||||||||||
IC50& Target | Estrogen receptor[1] | ||||||||||||||||
体外研究 (In Vitro) | The ability of Gypenoside XVII (GP-17) to prevent Ox-LDL-induced cytotoxicity is detected by cell viability assays. Gypenoside XVII does not demonstrate any cytotoxicity in HUVECs. Gypenoside XVII can protect HUVECs against Ox-LDL-induced apoptosis. Gypenoside XVII dose-dependently mitigates the toxic effect of Ox-LDL on HUVEC viability. The viability of HUVECs is significantly higher than that of other groups at 50 μg/mL Gypenoside XVII[1]. | ||||||||||||||||
体内研究 (In Vivo) | Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE-/-mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE-/-model group[1]. | ||||||||||||||||
分子量 | 947.15 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C48H82O18 | ||||||||||||||||
CAS 号 | 80321-69-3 | ||||||||||||||||
中文名称 | 七叶胆苷 XVII;绞股蓝皂苷 XVII | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(105.58 mM) H2O : 41.67 mg/mL(44.00 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|